147 related articles for article (PubMed ID: 34050131)
1. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.
Arulananda S; O'Brien M; Evangelista M; Jenkins LJ; Poh AR; Walkiewicz M; Leong T; Mariadason JM; Cebon J; Balachander SB; Cidado JR; Lee EF; John T; Fairlie WD
Cell Death Discov; 2021 May; 7(1):122. PubMed ID: 34050131
[TBL] [Abstract][Full Text] [Related]
2. BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.
Arulananda S; O'Brien M; Evangelista M; Harris TJ; Steinohrt NS; Jenkins LJ; Walkiewicz M; O'Donoghue RJJ; Poh AR; Thapa B; Williams DS; Leong T; Mariadason JM; Li X; Cebon J; Lee EF; John T; Fairlie WD
Cell Death Discov; 2020 Oct; 6(1):114. PubMed ID: 33298868
[TBL] [Abstract][Full Text] [Related]
3. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
[TBL] [Abstract][Full Text] [Related]
4. The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma.
Arulananda S; Lee EF; Fairlie WD; John T
Expert Rev Anticancer Ther; 2021 Apr; 21(4):413-424. PubMed ID: 33238762
[No Abstract] [Full Text] [Related]
5. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
6. Malignant pleural mesothelioma co-opts BCL-X
Xu D; Liang SQ; Yang Z; Yang H; Bruggmann R; Oberhaensli S; Berezowska S; Marti TM; Hall SRR; Dorn P; Kocher GJ; Schmid RA; Peng RW
Cell Death Dis; 2021 Apr; 12(4):406. PubMed ID: 33859162
[TBL] [Abstract][Full Text] [Related]
7. Design and optimisation of dendrimer-conjugated Bcl-2/x
Patterson CM; Balachander SB; Grant I; Pop-Damkov P; Kelly B; McCoull W; Parker J; Giannis M; Hill KJ; Gibbons FD; Hennessy EJ; Kemmitt P; Harmer AR; Gales S; Purbrick S; Redmond S; Skinner M; Graham L; Secrist JP; Schuller AG; Wen S; Adam A; Reimer C; Cidado J; Wild M; Gangl E; Fawell SE; Saeh J; Davies BR; Owen DJ; Ashford MB
Commun Biol; 2021 Jan; 4(1):112. PubMed ID: 33495510
[TBL] [Abstract][Full Text] [Related]
8. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x
Balachander SB; Criscione SW; Byth KF; Cidado J; Adam A; Lewis P; Macintyre T; Wen S; Lawson D; Burke K; Lubinski T; Tyner JW; Kurtz SE; McWeeney SK; Varnes J; Diebold RB; Gero T; Ioannidis S; Hennessy EJ; McCoull W; Saeh JC; Tabatabai A; Tavana O; Su N; Schuller A; Garnett MJ; Jaaks P; Coker EA; Gregory GP; Newbold A; Johnstone RW; Gangl E; Wild M; Zinda M; Secrist JP; Davies BR; Fawell SE; Gibbons FD
Clin Cancer Res; 2020 Dec; 26(24):6535-6549. PubMed ID: 32988967
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models.
Cucarull B; Tutusaus A; Subías M; Stefanovic M; Hernáez-Alsina T; Boix L; Reig M; García de Frutos P; Marí M; Colell A; Bruix J; Morales A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32024199
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
Varin E; Denoyelle C; Brotin E; Meryet-Figuière M; Giffard F; Abeilard E; Goux D; Gauduchon P; Icard P; Poulain L
Carcinogenesis; 2010 Jun; 31(6):984-93. PubMed ID: 20142415
[TBL] [Abstract][Full Text] [Related]
12. Mesothelioma Cells Depend on the Antiapoptotic Protein Bcl-xL for Survival and Are Sensitized to Ionizing Radiation by BH3-Mimetics.
Jackson MR; Ashton M; Koessinger AL; Dick C; Verheij M; Chalmers AJ
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(4):867-877. PubMed ID: 31786278
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting BCL-X
Khan S; Kellish P; Connis N; Thummuri D; Wiegand J; Zhang P; Zhang X; Budamagunta V; Hua N; Yang Y; De U; Jin L; Zhang W; Zheng G; Hromas R; Hann C; Zajac-Kaye M; Kaye FJ; Zhou D
Cell Death Discov; 2023 Jan; 9(1):1. PubMed ID: 36588105
[TBL] [Abstract][Full Text] [Related]
14. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
Zhang L; Ramesh P; Steinmetz M; Medema JP
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
[TBL] [Abstract][Full Text] [Related]
15. Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck.
Carter RJ; Milani M; Butterworth M; Alotibi A; Harper N; Yedida G; Greaves G; Al-Zebeeby A; Jorgensen AL; Schache AG; Risk JM; Shaw RJ; Jones TM; Sacco JJ; Hurlstone A; Cohen GM; Varadarajan S
Cell Death Dis; 2019 Dec; 10(12):912. PubMed ID: 31801952
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of Bcl-xL enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma H-2452 cells.
Lee YJ; Hwang IS; Lee YJ; Lee CH; Kim SH; Nam HS; Choi YJ; Lee SH
J Korean Med Sci; 2014 Nov; 29(11):1464-72. PubMed ID: 25408576
[TBL] [Abstract][Full Text] [Related]
17. BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells.
Reinhart R; Rohner L; Wicki S; Fux M; Kaufmann T
Cell Death Differ; 2018 Jan; 25(1):204-216. PubMed ID: 28960207
[TBL] [Abstract][Full Text] [Related]
18. MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.
Vikström IB; Slomp A; Carrington EM; Moesbergen LM; Chang C; Kelly GL; Glaser SP; Jansen JH; Leusen JH; Strasser A; Huang DC; Lew AM; Peperzak V; Tarlinton DM
Cell Death Dis; 2016 Aug; 7(8):e2345. PubMed ID: 27560714
[TBL] [Abstract][Full Text] [Related]
19. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
Smythe WR; Mohuiddin I; Ozveran M; Cao XX
J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1191-8. PubMed ID: 12063468
[TBL] [Abstract][Full Text] [Related]
20. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
